| Method for measuring neurotoxicity of aggregating polypeptides with the MTT assay on differentiated neuroblastoma cells Z Datki, A Juhász, M Gálfi, K Soós, R Papp, D Zádori, B Penke Brain research bulletin 62 (3), 223-229, 2003 | 204 | 2003 |
| Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease D Zádori, G Nyiri, A Szőnyi, I Szatmári, F Fülöp, J Toldi, TF Freund, ... Journal of neural transmission 118 (6), 865-875, 2011 | 103 | 2011 |
| Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease D Zádori, A Geisz, E Vámos, L Vécsei, P Klivényi Pharmacology Biochemistry and Behavior 94 (1), 148-153, 2009 | 93 | 2009 |
| Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders D Zádori, P Klivényi, L Szalárdy, F Fülöp, J Toldi, L Vécsei Journal of the neurological sciences 322 (1-2), 187-191, 2012 | 89 | 2012 |
| Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies D Zádori, P Klivényi, E Vámos, F Fülöp, J Toldi, L Vécsei Journal of neural transmission 116 (11), 1403-1409, 2009 | 83 | 2009 |
| Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets D Zádori, G Veres, L Szalárdy, P Klivényi, J Toldi, L Vécsei Journal of Alzheimer's Disease 42 (s3), S177-S187, 2014 | 75 | 2014 |
| In vitro model of neurotoxicity of Aβ 1–42 and neuroprotection by a pentapeptide: irreversible events during the first hour Z Datki, R Papp, D Zádori, K Soós, L Fülöp, A Juhász, G Laskay, ... Neurobiology of disease 17 (3), 507-515, 2004 | 75 | 2004 |
| Alzheimer’s disease: recent concepts on the relation of mitochondrial disturbances, excitotoxicity, neuroinflammation, and kynurenines D Zádori, G Veres, L Szalárdy, P Klivényi, L Vécsei Journal of Alzheimer's Disease 62 (2), 523-547, 2018 | 73 | 2018 |
| Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives F Fulop, I Szatmári, E Vámos, D Zádori, J Toldi, L Vécsei Current medicinal chemistry 16 (36), 4828-4842, 2009 | 67 | 2009 |
| Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis–osteopontin as a potential marker of clinical severity L Szalardy, D Zadori, M Simu, K Bencsik, L Vecsei, P Klivenyi Journal of the neurological sciences 331 (1-2), 38-42, 2013 | 60 | 2013 |
| Manipulating kynurenic acid levels in the brain–on the edge between neuroprotection and cognitive dysfunction L Szalardy, D Zadori, J Toldi, F Fulop, P Klivenyi, L Vecsei Current topics in medicinal chemistry 12 (16), 1797-1806, 2012 | 60 | 2012 |
| Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects L Szalárdy, P Klivényi, D Zádori, F Fulop, J Toldi, L Vécsei Current medicinal chemistry 19 (13), 1899-1920, 2012 | 58 | 2012 |
| Gray matter is targeted in first-attack multiple sclerosis SE Schutzer, TE Angel, T Liu, AA Schepmoes, F Xie, J Bergquist, L Vécsei, ... PloS one 8 (9), e66117, 2013 | 56 | 2013 |
| Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines D Zádori, P Klivényi, I Plangár, J Toldi, L Vécsei Journal of cellular and molecular medicine 15 (4), 701-717, 2011 | 49 | 2011 |
| Kynurenines in Parkinson’s disease: therapeutic perspectives D Zádori, P Klivényi, J Toldi, F Fülöp, L Vécsei Journal of neural transmission 119 (2), 275-283, 2012 | 43 | 2012 |
| Drug-induced movement disorders D Zadori, G Veres, L Szalárdy, P Klivényi, L Vécsei Expert Opinion on Drug Safety 14 (6), 877-890, 2015 | 38 | 2015 |
| Neuroprotection in Parkinson’s disease: facts and hopes A Salamon, D Zádori, L Szpisjak, P Klivényi, L Vécsei Journal of neural transmission 127 (5), 821-829, 2020 | 36 | 2020 |
| Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: an open-label study A Juhász, Z Aschermann, P Ács, J Janszky, M Kovács, A Makkos, ... Parkinsonism & Related Disorders 37, 79-86, 2017 | 35 | 2017 |
| Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy I Plangár, D Zádori, P Klivényi, J Toldi, L Vécsei Journal of Alzheimer's Disease 24 (s2), 199-209, 2011 | 28 | 2011 |
| Electron transport disturbances and neurodegeneration: From albert Szent-Györgyi’s concept (Szeged) till novel approaches to boost mitochondrial bioenergetics L Szalárdy, D Zádori, P Klivényi, J Toldi, L Vécsei Oxidative medicine and cellular longevity 2015, 2015 | 27 | 2015 |
